This symposium will be organized into 3 sessions. Each session will cover a specific topic related to the ethics of preclinical detection viewed through the lens of either autism spectrum disorder, Schizophrenia, and Alzheimer’s disease, respectively.The progression of each session will allow attendees to experience how the ethical issues surrounding preclinical detection arise through three disorders that arise at specific developmental time points. Each session will include talks from a scientific expert on the disorder, a prominent ethicist, and a testimonial from patient or family member
This session will have a special focus on the ethics of conducting preclinical research (informed consent, how to communicate with patients notions of “risk” and trying to convince parents of infants to continue in the study if they don’t believe the “high risk” assessment) while focusing on autism spectrum disorder.
Including talks from Dr. Cheryl Klaiman and Dr. Paul Root Wolpe.
This session will have a special focus on the ethics of interventions/treatment to patients who are considered prodromal for schizophrenia, given high risk for physical harm for the developing brain for adolescents who may never actually develop schizophrenia).
Including a talk from Dr. Elaine Walker and Dr. Donna Chen
This session will have special focus on the ethics of delivering a preclinical diagnosis given the risks for stigma (as well as impact on insurability) for Alzheimer’s disease.
Including talks from Dr. Allan Levey and Dr. Dena Davis
The symposium will take place on April 28th, 2017 from 9:30AM to 4:30PM. You are welcomed to join for any session of the event.